Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rosetta Genomics, a molecular diagnostic company, has closed its previously announced licensing and collaboration transaction with Prometheus Laboratories, a specialty pharmaceutical company.
Subscribe to our email newsletter
Pursuant to the terms of the agreement, Rosetta has granted Prometheus US rights to three recently introduced, microRNA-based cancer diagnostic tests: miRview mets, miRview squamous and miRview meso.
In conjunction with the closing of the licensing transaction, the parties also closed the previously announced purchase of two million Rosetta ordinary shares by Prometheus at $4 per share.